Compare Halliburton Company (HAL) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halliburton Company vs Regeneron Pharmaceuticals Inc — how do they compare? Halliburton Company trades at $33.19 (market cap $29.33B), while Regeneron Pharmaceuticals Inc trades at $669.77 (market cap $70.47B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 2.4× Halliburton Company's market cap, and Halliburton Company pays the higher dividend (1.94%). Which is the better fit depends on your goals.
| HAL | REGN | |
|---|---|---|
Market Cap | $29.33B | $70.47B |
Sector | Energy | Health |
52-Week High | $42.98 | $812.27 |
52-Week Low | $20.50 | $545.46 |
Enterprise Value | $35.41B | $64.42B |
Dividend Yield | 1.94% | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Halliburton (HAL) trades at $35.56, up 0.97% on the day, with a bullish technical signal supported by moving averages. The company shows solid fundamentals with a P/E of 19.46 and ROE of 14.56%, though net income declined to $1.28B in 2025. Recent contract wins with Aramco in Saudi Arabia and TotalEnergies in Suriname highlight growth opportunities, while analyst consensus is strongly bullish with a $44.78 price target.
Outlook remains positive due to strategic contracts and oil price support from geopolitical tensions, but risks include Middle East volatility and cost pressures. The stock offers value with earnings beats and institutional backing, though investors should monitor debt levels and execution on new projects.
Regeneron Pharmaceuticals (REGN) trades at $671.9, down 0.71% on the day, with a bullish technical signal and strong fundamentals. The stock shows robust profitability with a 29.65% net income margin and consistent earnings beats in recent quarters. Analyst consensus is strongly bullish with a $764.50 price target, though recent news highlights a securities class action lawsuit filed in July 2026.
Outlook remains positive due to solid financials and analyst support, but risks include legal uncertainties from ongoing litigation and potential market volatility. The stock offers value with a P/E of 16.52, trading below the consensus target, presenting upside if legal concerns resolve favorably.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Halliburton Company
Halliburton is one of the three largest oilfield service firms in the world, offering superior expertise in a number of business lines, including completion fluids, wireline services, cementing, and countless others. It's the number one pressure pumper in North America, and has been a leading innovator in hydraulic fracturing over the last two decades.
Read more on HAL →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
